Axicabtagene ciloleucel for large B-cell lymphoma: Ethics and implementation report
Axicabtagene ciloleucel (marketed as Yescarta by Gilead Sciences) is the second chimeric antigen receptor (CAR) T-cell therapy to be approved in Canada. Following a priority review, Health Canada approved axicabtagene ciloleucel on February 13, 2019, for the treatment of adult patients with relapsed...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
August 2019, 2019
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references